Insider · CIK 0001266773
Jack W Callicutt
Files at GALT (GALECTIN THERAPEUTICS INC). First filing Dec 26, 2024, latest Jan 6, 2026.
Jack W Callicutt files SEC Form 4 as CFO at GALT (GALECTIN THERAPEUTICS INC). Since Dec 26, 2024, Jack W Callicutt has reported 0 open-market buys worth $0 and 7 open-market sells worth $1.0M, the latest filed on Jan 6, 2026.
A track record needs three past buys with six months of prices behind them; Jack W Callicutt has 0, so none is measured yet.
The newest scored trade: sold $233k of GALT on Jan 2, 2026, filed Jan 6, 2026, scored 35 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $944k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GALT: GALECTIN THERAPEUTICS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | GALECTIN THERAPEUTICS INC | $233k 60,000 shares | -89% | +268% from low-38% from high | |
| 40Moderate | GALECTIN THERAPEUTICS INC | $479k 77,920 shares | -453% | +614% from low0% from high | |
| 27Weak | GALECTIN THERAPEUTICS INC | $32k 5,291 shares | -56% | +519% from low-13% from high | |
| 2Weak | GALECTIN THERAPEUTICS INC | $3,600 600 shares | -8% | +570% from low-6% from high | |
| 34Weak | GALECTIN THERAPEUTICS INC | $197k 32,439 shares | -364% | +614% from low0% from high | |
| 22Weak | GALECTIN THERAPEUTICS INC | $56k 8,706 shares | -53% | +539% from low-10% from high | |
| 28Weak | GALECTIN THERAPEUTICS INC | $35k 40,000 shares | -84% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | 141,206 0.22% of outstanding | $593k | Jan 2, 2026 | $710k |
| Sep 12, 2025 | GALT GALECTIN THERAPEUTICS INC | 141,206 0.22% of outstanding | $909k | Sep 12, 2025 | none |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | 40,000 0.06% of outstanding | $42k | Dec 23, 2024 | none |
Transactions
The newest 50 of 66 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock option (right to buy)derivative10b5-1 | +65,000 | $0.00 | $0 | 65,000 | Jan 21, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Restricted Stock Unitderivative10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Jan 21, 2026 |
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +60,000 | $0.00 | $0 | 67,614 | Jan 6, 2026 |
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -13,914 | $4.20 | $58k | 53,700 | Jan 6, 2026 |
| Jan 5, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -25,732 | $3.90 | $100k | 27,968 | Jan 6, 2026 |
| Jan 6, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -20,354 | $3.67 | $75k | 7,614 | Jan 6, 2026 |
| Jan 1, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Restricted Stock Unitderivative10b5-1 | -60,000 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +9,586 | $1.98 | $19k | 17,200 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -9,586 | $6.03 | $58k | 7,614 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +19,701 | $1.11 | $22k | 27,315 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -19,701 | $6.03 | $119k | 7,614 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +2,323 | $1.23 | $2,857 | 9,937 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -2,323 | $6.03 | $14k | 7,614 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +28,100 | $1.98 | $56k | 35,714 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -28,100 | $6.22 | $175k | 7,614 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +18,210 | $1.11 | $20k | 25,824 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -18,210 | $6.22 | $113k | 7,614 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -9,586 | $0.00 | $0 | 28,120 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -19,701 | $0.00 | $0 | 18,190 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -2,323 | $0.00 | $0 | 48,750 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -28,120 | $0.00 | $0 | 0 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock (right to buy)derivative10b5-1 | -18,190 | $0.00 | $0 | 0 | Nov 19, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +1,880 | $1.98 | $3,722 | 9,694 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -1,880 | $6.02 | $11k | 7,614 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +1,675 | $1.11 | $1,859 | 9,289 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -1,675 | $6.03 | $10k | 7,614 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +1,736 | $1.23 | $2,135 | 9,350 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -1,736 | $6.03 | $10k | 7,614 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -1,880 | $0.00 | $0 | 37,706 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -1,675 | $0.00 | $0 | 37,891 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -1,736 | $0.00 | $0 | 51,073 | Nov 12, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +200 | $1.98 | $396 | 7,814 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -200 | $6.00 | $1,200 | 7,614 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +200 | $1.11 | $222 | 7,814 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -200 | $6.00 | $1,200 | 7,614 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +200 | $1.72 | $344 | 7,814 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -200 | $6.00 | $1,200 | 7,614 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -200 | $0.00 | $0 | 39,586 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -200 | $0.00 | $0 | 39,566 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -200 | $0.00 | $0 | 52,809 | Nov 7, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +1,300 | $1.98 | $2,574 | 8,914 | Nov 5, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -1,300 | $6.01 | $7,813 | 7,614 | Nov 5, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +1,260 | $1.11 | $1,399 | 8,874 | Nov 5, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -1,260 | $6.01 | $7,573 | 7,614 | Nov 5, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +1,250 | $1.72 | $2,150 | 8,864 | Nov 5, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Commno stock10b5-1 | -1,250 | $6.01 | $7,513 | 7,614 | Nov 5, 2025 |
| Nov 4, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +8,914 | $1.98 | $18k | 16,528 | Nov 5, 2025 |
| Nov 4, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -8,914 | $6.07 | $54k | 7,614 | Nov 5, 2025 |
| Nov 4, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common stock10b5-1 | +8,974 | $1.11 | $9,961 | 16,588 | Nov 5, 2025 |
| Nov 4, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common stock10b5-1 | -8,974 | $6.07 | $54k | 7,614 | Nov 5, 2025 |
Questions about Jack W Callicutt
Answered from the filings on this page, as of the latest one.
Is Jack W Callicutt buying or selling?
In the last 12 months Jack W Callicutt reported 0 open-market buys worth $0 and 5 open-market sells worth $944k on SEC Form 4; the latest was sold $233k of GALT on Jan 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Jack W Callicutt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jack W Callicutt has 0.
Where does Jack W Callicutt file Form 4?
Jack W Callicutt has filed Form 4 at GALT (GALECTIN THERAPEUTICS INC) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.